TTD Drug ID: DAP001515

Drug Information
Name	Ropinirole HCl
Synonyms	91374-20-8; UNII-D7ZD41RZI9; Ropinirole HCl; MolPort-003-987-439; Requip (TN); SKF 101468; 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride; JZP-7; 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one hydrochloride; SKF 101468-A; AC-735; Ropinirole hydrochloride [USAN]; NCGC00094373-01; 2(H)-Indol-2-one, 4-(2-(dipropylamino)ethyl)-1,3-dihydro-, monohydrochloride; AC1Q3EQJ; Repreve; 2H-Indol-2-one, 1,3-dihydro-4-(2-(dipropylamino)ethyl)-, monohydrochloride; AR-1L3132; AC1L2ABS; Ropinirole hydrochloride (JAN/USAN); 4-(2-(Dipropylamino)ethyl)-2-indolinone monohydrochloride; ST51051236; I06-0693; ReQuip CR; R 4152; Ropinirole hydrochloride; 1,3-Dihydro-4-(2-(dipropylamino)ethyl)-2H-indol-2-one monohydrochloride; SK&F-101468A; 2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]-1,3-dihydro-, hydrochloride (1:1); ReQuip; CID68727; TL8005858; SK&F-101468-A; CHEMBL1200411; ReQuip XL; LS-83828; 91374-21-9 (Parent); SK&F 101468-A; ReQuip XR; ReQuip LP; Adartrel; D00784; EU-0101101; NVD-434
Indication	Parkinson's Disease			Approved    [1]
Structure	Click to save drug structure in 3D MOL format Click to save drug structure in 2D MOL format
InChI	1S/C16H24N2O.ClH/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19 )17-15;/h5-7H,3-4,8-12H2,1-2H3,(H,17,19);1H
InChIKey	XDXHAEQXIBQUEZ-UHFFFAOYSA-N
Canonical SMILES	CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl
CAS Number	CAS 91374-21-9
PubChem Compound ID	CID 68727.
PubChem Substance ID	SID 210858.
ChEBI	8888;
SuperDrug ATC ID	N04BC04
SuperDrug CAS ID	091374219;
Target	Dopamine receptor			Agonist	[1]
Ref 1	Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. To Reference

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.